Medication info
Sinubi MXR Extended Release Tablet 100/1000 mg (Sitagliptin, Metformin)

Sinubi MXR Extended Release Tablet 100/1000 mg (Sitagliptin, Metformin)

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›113.4mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Samjin Pharmaceutical Co., Ltd.
Appearance
A bright blue, oval-shaped, bilaterally convex extended-release film-coated tablet
Packaging
28 tablets/bottle, 56 tablets/bottle, 200 tablets/bottle
Approval status
Active

MFDS item code 202201966 · Approved 2022.05.11 · Insurance code 647805460

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medication for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, this medication should be taken with a meal once daily, preferably in the evening, and the dose should be increased gradually. To maintain its extended-release properties, this medication must be swallowed whole without splitting, crushing, grinding, or chewing. Take 1 tablet of this medication 100/1000 mg extended-release tablet once daily. Patients taking this medication 50/500 mg extended-release tablet or 50/1000 mg extended-release tablet should take 2 tablets together once daily. 1. Patients not currently receiving metformin: For patients with no prior experience of antidiabetic drug treatment who have difficulty achieving adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial total daily dose of this medication is sitagliptin 100 mg and metformin 1000 mg. If adequate glycemic control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medication. 2. Patients receiving metformin: - The recommended initial total daily dose of this medication for patients who cannot achieve adequate glycemic control with metformin monotherapy is sitagliptin 100 mg and their current dose of metformin. - Patients switching to this medication from concomitant sitagliptin and metformin therapy may start at their current doses of sitagliptin and metformin. - Patients taking immediate-release metformin at a current dose of 850 mg or 1000 mg twice daily may start with 2 tablets of this medication 50/1000 mg extended-release tablet once daily. 3. Patients unable to achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this medication is sitagliptin 100 mg, and the initial dose of metformin should be determined based on the patient's blood glucose level and current dose. Increase the dose gradually to reduce gastrointestinal adverse reactions caused by metformin. When administered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin. Patients with renal impairment This medication may be used, with the following dosage adjustment, in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis. Since the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medication. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medication must be discontinued immediately.

Ingredients

Manufacturer
Samjin Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This drug is used to treat type 2 diabetes mellitus and helps control blood sugar levels in patients who are also on diet and exercise therapy. Sitagliptin and metformin work together to effectively lower blood sugar. Therefore, it is used as a suitable treatment for patients with type 2 diabetes who require blood sugar management.

How to take

Adult dose

The dose of this medication for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, this medication should be taken with a meal once daily, preferably in the evening, and the dose should be increased gradually. To maintain its extended-release properties, this medication must be swallowed whole without splitting, crushing, grinding, or chewing. Take 1 tablet of this medication 100/1000 mg extended-release tablet once daily. Patients taking this medication 50/500 mg extended-release tablet or 50/1000 mg extended-release tablet should take 2 tablets together once daily. 1. Patients not currently receiving metformin: For patients with no prior experience of antidiabetic drug treatment who have difficulty achieving adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial total daily dose of this medication is sitagliptin 100 mg and metformin 1000 mg. If adequate glycemic control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medication. 2. Patients receiving metformin: - The recommended initial total daily dose of this medication for patients who cannot achieve adequate glycemic control with metformin monotherapy is sitagliptin 100 mg and their current dose of metformin. - Patients switching to this medication from concomitant sitagliptin and metformin therapy may start at their current doses of sitagliptin and metformin. - Patients taking immediate-release metformin at a current dose of 850 mg or 1000 mg twice daily may start with 2 tablets of this medication 50/1000 mg extended-release tablet once daily. 3. Patients unable to achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this medication is sitagliptin 100 mg, and the initial dose of metformin should be determined based on the patient's blood glucose level and current dose. Increase the dose gradually to reduce gastrointestinal adverse reactions caused by metformin. When administered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin. Patients with renal impairment This medication may be used, with the following dosage adjustment, in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis. Since the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medication. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medication must be discontinued immediately.

Precautions

This drug contains sitagliptin and metformin and is used for diabetes treatment. Sitagliptin can rarely cause serious allergic reactions, so if symptoms such as rash or difficulty breathing occur, discontinue use immediately and consult a physician. Additionally, acute pancreatitis may occur, so if there is abdominal pain, vomiting, or severe abdominal pain, seek medical attention immediately. Metformin can cause rare but serious side effects such as lactic acidosis, so if symptoms such as shortness of breath, muscle pain, fatigue, or abdominal pain occur, notify medical personnel immediately. Patients with moderate to severe renal impairment, dehydrated individuals, those with severe infections, congestive heart failure, acute myocardial infarction, or conditions that may affect renal function should not take this medication. Additionally, it should not be administered to pregnant women or breastfeeding women. During the use of this medication, it is important to undergo regular renal function tests and check vitamin B12 levels. Alcohol should be avoided, and in case of sudden surgery or radiologic examinations using contrast agents, medication should be temporarily discontinued. There is a risk of hypoglycemia, so if taken together with other diabetic medications such as insulin or sulfonylureas, blood sugar should be checked frequently and attention should be paid to symptoms of hypoglycemia. Be cautious of unusual symptoms like hypoglycemia or drowsiness while performing tasks requiring attention, such as driving or operating machinery. If blisters appear on the skin or if severe joint pain occurs during medication use, notify a physician immediately. This medication has not been established for safety and efficacy in patients under 18 years of age, and should not be used.

Side effects

anaphylaxis, angioedema, Stevens-Johnson syndrome, acute pancreatitis, lactic acidosis, hypoglycemia, diarrhea, upper respiratory tract infection, headache, nausea, vomiting, abdominal pain, nasopharyngitis, constipation, severe and disability-associated arthralgia, bullous pemphigoid, myalgia, limb pain, back pain, interstitial lung disease, pruritus, thrombocytopenia, rhabdomyolysis, rash, urticaria, cutaneous vasculitis, elevated liver enzymes, acute renal failure, hypoglycemic episode, peripheral edema

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to protect it from air and moisture, and it is important to maintain a storage temperature between 1 and 30 degrees Celsius. Therefore, it should be kept in a cool, dry place until use, and precautions should be taken to avoid exposure to direct sunlight or high temperatures.

Appearance and packaging

Appearance

A bright blue, oval-shaped, bilaterally convex extended-release film-coated tablet

Package unit

28 tablets/bottle, 56 tablets/bottle, 200 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.